LivaNova PLC (NASDAQ:LIVN) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC decreased its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 92.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 932 shares of the company’s stock after selling 12,039 shares during the quarter. Headlands Technologies LLC’s holdings in LivaNova were worth $37,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in LIVN. Wells Fargo & Company MN boosted its holdings in shares of LivaNova by 6.0% during the fourth quarter. Wells Fargo & Company MN now owns 220,782 shares of the company’s stock worth $10,224,000 after purchasing an additional 12,517 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in shares of LivaNova by 15.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company’s stock worth $2,034,000 after purchasing an additional 5,850 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after purchasing an additional 219 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of LivaNova by 0.6% during the fourth quarter. Invesco Ltd. now owns 111,374 shares of the company’s stock worth $5,158,000 after purchasing an additional 667 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of LivaNova by 9.2% during the fourth quarter. Renaissance Technologies LLC now owns 112,594 shares of the company’s stock worth $5,214,000 after purchasing an additional 9,500 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Barclays reduced their target price on LivaNova from $56.00 to $55.00 and set an “equal weight” rating on the stock in a report on Thursday, May 8th. Robert W. Baird lifted their target price on LivaNova from $55.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Finally, Wolfe Research upgraded LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a report on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $59.29.

LivaNova Price Performance

Shares of LivaNova stock opened at $53.06 on Thursday. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35. The stock has a market capitalization of $2.90 billion, a P/E ratio of -13.64 and a beta of 0.92. The company has a current ratio of 1.29, a quick ratio of 1.09 and a debt-to-equity ratio of 0.31. The business’s fifty day moving average price is $45.36 and its 200 day moving average price is $42.87.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.21. The company had revenue of $352.50 million for the quarter, compared to analysts’ expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.93 earnings per share. As a group, research analysts anticipate that LivaNova PLC will post 2.85 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.